Pharmaceuticals

Context Therapeutics

Context Therapeutics released FY2026 Q1 earnings on May 6, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0911 (forecast USD -0.115)

Context Therapeutics released FY2025 Annual Earnings on March 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3795 (forecast USD -0.35)

Context Therapeutics released FY2025 Q4 earnings on March 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1373 (forecast USD -0.106)

Context Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1018 (forecast USD -0.096)

Context Therapeutics released FY2025 9 Months Earnings on November 5 (EST), with actual revenue of USD 0 and EPS of USD -0.2445

Context Therapeutics Inc. to Present Posters on TCE Bispecific Antibodies

Context Therapeutics released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0927 (forecast USD -0.0625)

Context Therapeutics released FY2025 Semi-Annual Earnings on August 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1408

Context Therapeutics Gets Multiple Buy Recommendations

Piper Sandler Reiterates Context Therapeutics Rating and Adjusts Target Price

Chief Legal Officer of Context Therapeutics Buys Company Stock

Context Therapeutics Grants Non-Qualified Stock Options to New Employees

Context Therapeutics released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.05 (forecast USD -0.0633)

Context Therapeutics Reports Q1 2025 Net Loss of $4.6 Million

Context Therapeutics Displays Preclinical and Translational Data for CT-95

Context Therapeutics Inc. Initiates Phase I Clinical Trial for CT-95

Context Therapeutics Inc. Participates in Multiple Investor Meetings to Showcase Its T-Cell Antibodies

Context Therapeutics to Present Initial Human Dose Determination of CT-95 at the 2025 AACR Annual Meeting

Context Therapeutics released FY2024 Q4 earnings on March 20, 2025 (EST), with actual revenue of 0 USD and EPS of -0.0408 USD (forecast EPS -0.092 USD)

Context Therapeutics released FY2024 annual earnings on March 20 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.4574 USD (forecast -0.58 USD)

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

CNTX

LABU

SBIO

ARKG

IBBQ

Context Therapeutics Inc. (NASDAQ:CNTX) insiders have seen their investments yield positive returns despite a recent 10% stock drop. Over the past year, insiders bought shares worth US$107.1k, now valued at US$344.0k. The largest purchase was by Co-Founder Martin Lehr for US$70k at US$0.70 per share. Insiders currently hold about 1.4% of the stock, valued at US$2.7m, indicating a preference for higher insider ownership. Recent insider buying suggests confidence, but there are three significant warning signs to consider.

Simplywall

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Context Therapeutics Decline Means Insider Profits Down To US$237k

BCAB

Context Therapeutics has amended its license with BioAtla, agreeing to pay $6.5 million to secure perpetual, royalty-free rights to its antibody licenses, including CT-202. The amendment, effective May 14, 2026, removes R&D obligations and eliminates BioAtla's termination rights, ensuring Context retains full control without future milestone payments or royalties.

TradingView

BioAtla

Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

StockTitan

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

HC Wainwright has revised its FY2030 earnings per share estimate for Context Therapeutics Inc. (NASDAQ:CNTX) from $0.08 to $0.06. The consensus estimate for the company's current full-year earnings stands at ($0.49) per share. Various analysts have given mixed ratings on CNTX, with one Strong Buy, six Buy, and one Sell rating. The stock opened at $2.31, with a market cap of $211.78 million and a 52-week range of $0.49 to $3.62. Institutional investors hold 14.03% of the company's shares.

Market Beat

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VG Health

What is HC Wainwright's Estimate for CNTX FY2030 Earnings?

Context Therapeutics Inc. reported its first quarter 2026 financial results, revealing cash and cash equivalents of $54.5 million, expected to fund operations into mid-2027. The company anticipates Phase 1a interim data for CTIM-76 in June 2026 and CT-95 in September 2026. R&D expenses rose to $7.0 million, while the net loss increased to $8.7 million. Context received FDA Fast Track Designation for CTIM-76 and is preparing to initiate a Phase 1 trial for CT-202 in Australia.

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | CNTX Stock News

JonesTrading analyst Soumit Roy has maintained a Buy rating on Context Therapeutics (CNTX) with a price target of $7.00. Roy, who focuses on the Healthcare sector, has an average return of -7.2% and a 32.22% success rate on his stock recommendations. Additionally, Maxim Group's Jason McCarthy also issued a Buy rating for CNTX, while TipRanks reiterated a Hold rating on April 3.

Tip Ranks

iShares Global Healthcare

JonesTrading Remains a Buy on Context Therapeutics (CNTX)

Context Therapeutics(CNTX.US)

Context Therapeutics Decline Means Insider Profits Down To US$237k

Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News

What is HC Wainwright's Estimate for CNTX FY2030 Earnings?

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | CNTX Stock News

JonesTrading Remains a Buy on Context Therapeutics (CNTX)